Serina Therapeutics, Inc.SERNYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+227.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+227.9%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
35.3x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2024 | 213.23% |
| 2023 | 51.80% |
| 2022 | -58.59% |
| 2021 | 6.05% |
| 2020 | -33.00% |
| 2019 | -0.13% |
| 2018 | 1.63% |
| 2017 | -33.09% |
| 2016 | 0.00% |